The partnership will focus on accelerating drug development and scientific research in oncology and non-alcoholic steatohepatitis and will use PathAI’s digital pathology tools to do so.
“We look forward to leveraging both PathAI’s expertise and models to advance GSK’s proprietary AI models and focus on designing better models to deliver improved treatment options for patients with cancer and NASH,” said Kim Branson, Global Head of Artificial Intelligence and Machine Learning at GSK said in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.